Journal of Biological Chemistry
Volume 274, Issue 32, 6 August 1999, Pages 22877-22883
Journal home page for Journal of Biological Chemistry

PROTEIN CHEMISTRY AND STRUCTURE
Localization of a Substrate Specificity Domain in the Multidrug Resistance Protein*

https://doi.org/10.1074/jbc.274.32.22877Get rights and content
Under a Creative Commons license
open access

Multidrug resistance protein (MRP) confers resistance to a number of natural product chemotherapeutic agents. It is also a high affinity transporter of some physiological conjugated organic anions such as cysteinyl leukotriene C4 and the cholestatic estrogen, 17β-estradiol 17(β-d-glucuronide) (E217βG). We have shown that the murine orthologue of MRP (mrp), unlike the human protein, does not confer resistance to common anthracyclines and is a relatively poor transporter of E217βG. We have taken advantage of these functional differences to identify region(s) of MRP involved in mediating anthracycline resistance and E217βG transport by generating mrp/MRP hybrid proteins. All hybrid proteins conferred resistance to the Vinca alkaloid, vincristine, when transfected into human embryonic kidney cells. However, only those in which the COOH-terminal third of mrp had been replaced with the corresponding region of MRP-conferred resistance to the anthracyclines, doxorubicin, and epirubicin. Exchange of smaller segments of the COOH-terminal third of the mouse protein by replacement of either amino acids 959–1187 or 1188–1531 with those of MRP produced proteins capable of conferring some level of resistance to the anthracyclines tested. All hybrid proteins transported cysteinyl leukotriene C4 with similar efficiencies. In contrast, only those containing the COOH-terminal third of MRP transported E217βG with an efficiency comparable with that of the intact human protein. The results demonstrate that differences in primary structure of the highly conserved COOH-terminal third of mrp and MRP are important determinants of the inability of the murine protein to confer anthracycline resistance and its relatively poor ability to transport E217βG.

Cited by (0)

*

This work was supported by a grant from the National Cancer Institute of Canada with funds from the Terry Fox Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

Supported by an Ontario Graduate Scholarship and in part by a Queen's University graduate award.

A Senior Scientist of Cancer Care Ontario.